Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of COR-003 in healthy volunteers

Trial Profile

A study of COR-003 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levoketoconazole (Primary) ; Atorvastatin; Ketoconazole
  • Indications Cushing syndrome
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 10 May 2018 According to a Strongbridge Biopharma media release,Presented results from an in vitro study of levoketoconazole, the active ingredient in RECORLEV, at ENDO 2018, the Annual Meeting of the Endocrine Society
  • 06 Apr 2016 New trial record
  • 04 Apr 2016 According to a Strongbridge Biopharma media release, results from this study were presented at the Endocrine Society's 2016 Annual Meeting and Expo.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top